Estimation of Statistical Moments for Desferrioxamine and Its Iron and Aluminium Chelates: Contribution to Optimisation of Therapy in Uremic Patients

Nephron

Volumn 72, Issue 2, 1996, Pages 218-224

  Andriani, Mario ^a   Nordio, Maurizio ^b   Saporiti, Ernesto ^b  

^a Ospedale Civile   (Italy)

^b Ospedale Civile   (Italy)

Author keywords

Aluminoxamine; Desferrioxamine; Ferrioxamine; Hemodialysis; Mean arrival time; Mean residence time

Indexed keywords

DEFEROXAMINE; FERRIOXAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; HEMODIALYSIS; HUMAN; MEAN RESIDENCE TIME; PRIORITY JOURNAL; STATISTICAL ANALYSIS; UREMIA;

ALUMINUM; ANTIDOTES; CHELATING AGENTS; DATA INTERPRETATION, STATISTICAL; DEFEROXAMINE; DRUG ADMINISTRATION SCHEDULE; FERRIC COMPOUNDS; HEMOSIDEROSIS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RENAL DIALYSIS; UREMIA;

EID: 0030046549     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000188845     Document Type: Article

References (25)

1. Moeschlin S. Schnider U: Treatment of primary and secondary hemochromatosis and acute iron poisoning with a new, potent iron-eliminating agent, desferrioxaminc B. N Engl J Med 1963;269:57-66.
2. Ackrill SP, Ralston AJ. Day JP. Hodge KC: Successful removal of aluminum from patient with dialysis encephalopathy. Lancet 1980;ii; 693-694.
3. Kruck TPA, Kalow W: Determination of desferoxamine and a major metabolite by high-pressure liquid chromatography. J Chromatogr 1985;341:123-130.
4. Mattiello G, Rizzo F. Zoccolan R. Andriani M: High pressure liquid chromatography determination of low levels of free desferrioxamine and its iron and aliminium chelates: in Taylor A (ed): Aluminium and other trace elements in renal disease. London, Baillière Tindal. 1986, pp 241-245.
5. Allain P. Mauras Y. Beaudeau G, Hingonet P: Indirect microscale method for the determination of desferrioxamine and its aluminium and its iron chelates forms in biological samples by atomic absorption spectrometry with electrothermal atomisation. Analyst 1986:111:531-533.
6. D'Haese PC. Van de Vyver FL. de Wolff FA, De Broe ME: Measurement of aluminium in serum, blood, urine and tissues of chronic he-modialyzed patients by use of electrothermal atomic absorption spectrometry. Clin Client 1985;31:24-29.
7. Allain P. Chaleil D. Mauras Y. Beaudeau G. Venin MC. Paignet JL, Ciancioni C. Ang KS. Cam G, Simon P: Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on hemodialysis. Clin Chim Acta 1987:170:331-338.
8. D’Haese PC. Lamberts LV, De Broe ME: Indirect measurement of desferrioxamine and its chelated compounds aluminoxamine and fer-rioxamine by Zeeman atomic absorption spectrometry. Clin Chem 1989:35:884-887.
9. Veerpotcn GA, D’Haese PC, Bolaert JR. Be-cons J. Lamberts LV, De Broe ME: Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in hemodialysis patients. Nephrol Dial Transplant 1992:7:931-938.
10. Consensus Conference: Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Nephrol Dial Transplant 1993; 8:S1.
11. Veng-Pedersen P: Mean time parameters in pharmacokinetics. Definition, computation and clinical implications. Part I. Clin Pharma-cokinet 1989:17:345-366.
12. Veng-Pedersen P: Mean time parameters in pharmacokinetics. Definition, computation and clinical implications. Part II. Clin Pharma-cokinct 1989:17:424-440.
13. Dixon WJ, Brown MB. Engelmann L. Jennrich RI: BMDP Statistical Software Manual. Berkeley. University of California Press. 1990.
14. Canavcse C. Guniali L. D'Amieone M. Cardelli R. Caligaris F. Bongiorno P. Arnaud A. Mattiello G. Marchiori M: Kinetics of aluminoxamine and ferroxamine chelates in dialysis patients. Nephron 1992:60:411-417.
15. Charon SA. Chavassieux P. Chapny ML, Ac-cominatti M. Tuareg J. Meunieu PJ: Traitement par la desferrioxamine de l’ostéomalacie par intoxication à l'aluminium. Presse Méd 1986:15:55-59.
16. Simon P: Indications de la desferrioxamine chez les insuffisants rénaux chroniques traités par dialyse. Néphrologie 1986;5:177-180.
17. Malluclic HH, Smith AJ, Abreo K. Faugere MC: The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure. N Engl J Med 1985: 311:140-144.
18. Ackrill P. Day JP. Ahmed K: Aluminium and iron overload in chronic dialysis. Kidney Int 1989;33:163-167.
19. Baldamus CA, Schmidt I I. Schencrmann EH. Werner E. Kaltwasser JP, Schoeppe W: Desferrioxamine treatment for aluminium and iron overload in uraemic patients by haemodialysis or haemofiltration. Proc Eur Dial Transplant Assoc-ERA 1984:21:382-386.
20. Ackrill P: Aluminium removal by desferrioxamine: Clinical practice; in Taylor A (ed): Aluminium and other trace elements in renal disease. London. Baillière Tindal. 1986, pp 193-199.
21. Boelaerl JR, Fenzes AZ, Coburn JW: Deferoxamine therapy and mucormycosis in dialysis patients: Report of an international registry. Am J Kidney Dis 1991:18:660-667.
22. Van Cutsem J. Boelaerl JR: Effects of deferoxamine. ferroxamine and iron in experimental mucormycosis (zygomycosis). Kidney Int 1989:36:1061-1068.
23. Sherrard DJ. Walker JV, Boykin JL: Precipitation of dialysis dementia by desferoxamine treatment of aluminium-related bone disease. Am J Kidney Dis 1988:XII: 126-130.
24. Allain P. Mauras Y. Challel D, Simon P. Anf KS, Cam G, Le Megnon L, Simon M: Pharmacokinetics and renal elimination for desferiox-antine and ferioxamine in healthy subjects and patients with haemochromatosis. Br J Clin Pharmacol 1987;24:207-212.
25. Summers MR. Jacobs A. Tual Way D. Perera P, Ricketts L: Studies on desferioxamine and ferrioxamine metabolism in normal and iron loaded subjects. Br J Haematol 1979:42:547-555.